Related Experiment Video
Updated: Jan 25, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Dihydrotanshinone-Induced NOX5 Activation Inhibits Breast Cancer Stem Cell through the ROS/Stat3 Signaling Pathway
Su-Lim Kim1, Hack Sun Choi1,2,3, Ji-Hyang Kim1
1Department of Biotechnology, College of Applied Life Science, Jeju National University, Jeju, Republic of Korea.
Abstract:
Cancer stem cells (CSCs) are known to mediate metastasis and recurrence and are therefore a promising therapeutic target. In this study, we found that dihydrotanshinone (DHTS) inhibits CSC formation. DHTS inhibited mammosphere formation in a dose-dependent manner and showed significant tumor growth inhibition in a xenograft model. This compound reduced the CD44high/CD24low- and aldehyde dehydrogenase- (ALDH-) expressing cell population and the self-renewal-related genes Nanog, SOX2, OCT4, C-Myc, and CD44. DHTS induced NOX5 activation by increasing calcium, and NOX5 activation induced reactive oxygen species (ROS) production. ROS production reduced the nuclear phosphorylation levels of Stat3 and secreted IL-6 levels in the mammospheres. DHTS deregulated the dynamic equilibrium from non-stem cancer cells to CSCs by dephosphorylating Stat3 and decreasing IL-6 secretion and inhibiting CSC formation. These novel findings showed that DHTS-induced ROS deregulated the Stat3/IL-6 pathway and induced CSC death. NOX5 activation by DHTS inhibits CSC formation through ROS/Stat3/IL-6 signaling, and DHTS may be a promising potential therapeutic agent against breast CSCs.
Insights
Dihydrotanshinone (DHTS) effectively inhibits cancer stem cell (CSC) formation and breast tumor growth. DHTS targets the ROS/Stat3/IL-6 pathway, offering a potential therapeutic strategy against CSCs.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer stem cells (CSCs) drive tumor metastasis and recurrence, representing critical therapeutic targets.
- Identifying novel agents that selectively target CSCs is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To investigate the efficacy of dihydrotanshinone (DHTS) in inhibiting cancer stem cell formation and identify its underlying molecular mechanisms.
- To evaluate DHTS as a potential therapeutic agent against breast CSCs.
Main Methods:
- Assessed DHTS effects on mammosphere formation and xenograft tumor growth.
- Quantified CSC populations (CD44high/CD24low, ALDH-expressing) and self-renewal genes (Nanog, SOX2, OCT4, C-Myc, CD44).
- Investigated DHTS-induced NOX5 activation, calcium influx, reactive oxygen species (ROS) production, Stat3 phosphorylation, and IL-6 secretion.
Main Results:
- DHTS demonstrated dose-dependent inhibition of mammosphere formation and significant tumor growth reduction in vivo.
- DHTS decreased CSC populations and downregulated key self-renewal genes.
- DHTS activated NOX5, leading to increased ROS production, which subsequently reduced Stat3 phosphorylation and IL-6 secretion, thereby disrupting the CSC self-renewal pathway.
Conclusions:
- DHTS inhibits CSC formation by inducing ROS production via NOX5 activation, leading to the deregulation of the Stat3/IL-6 signaling pathway.
- These findings highlight DHTS as a promising therapeutic agent for targeting breast CSCs and overcoming treatment resistance.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Inhibition of Cdk Activity
Insulin: The Receptor and Signaling Pathways

